Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/THES-ACQU-109461274/news/POINT-Biopharma-Announces-First-Patients-Dosed-in-Phase-3-Study-of-PNT2002-for-mCRPC-35531489/?utm_source=whatsapp&utm_medium=social&utm_campaign=share